Combinatorial-designed Hyaluronic Acid Nanoparticles for Tumour Targeted Drug and Small Interfering Ribonucleic Acid Delivery - Hyaluronic Acid for Biomedical and Pharmaceutical Applications - page 77

1.2 1.2

A549 DDP
~20%

A549

1
0.8
0.6

1
0.8
0.6

~55%

0.4
0.2
0

0.4
0.2
0

1.2 H69 1.2

H69AR

1
0.8
0.6

1
0.8
0.6

0.4
0.2
0

0.4
0.2
0

Figure 3.6 In vivo gene knockdown activity mediated by siRNA
loaded HA nanosystems. Sensitive/resistant tumour (A549/
A549 DDP and H69/H69AR) bearing mice were injected with PLK1
or Sjögren syndrome antigen-B (SSB) siRNA encapsulated HA-
PEI/HA-PEG nanosystem at 0.5 mg/kg for 3 days. After 24 h
following the last injection, tumours were harvested and RNA was
extracted. qPCR was run to determine the target gene knockdown.
Adapted from S. Ganesh, A.K. Iyer, D.V. Morrissey and
M.M. Amiji, Biomaterials , 2013, 34 , 3489 [19]